TOWARD MODELING PSYCHOMOTOR PERFORMANCE IN KARATE COMBATS USING COMPUTER VISION POSE ESTIMATION



ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone (ELd) for Outdoor Loveseat Glider with Cushion relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomized trial ELOQUENT-2 (NCT01239797).Four-year follow-up analyses

read more